COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,999 Articles (22,627 medRxiv, 8,372 bioRxiv)

Most recent first Previous |  Page 447: Articles 4461-4470  | Next

The infectivity of SARS-CoV-2 progeny virions requires the activity of host cell N-myristoyltransferases and it is severely compromised by their inhibition
Saber, S. H., Ojha, R., Quirin, T., Strandin, T., Yak, N., Kant, R., Kareinen, L., Sironen, T., Vapalahti, O., Balistreri, G., Joensuu, M.
10.1101/2023.03.03.530798 — Posted: 2023-03-03
Virological evidence of the impact of non-pharmaceutical interventions against COVID-19 in a resource-limited setting
Moreira-Soto, A., Bruno, A., de Mora, D., Paez, M., Garcez, J., Wulf, B., Sander, A.-L., Olmedo, M., Basantes Mantilla, M. J., Gonzalez, M., Orlando Narvaez, A., Salgado Cisneros, S. P., Zevallos, J. C., Drexler, J.
10.1101/2023.03.01.23286616 — Posted: 2023-03-03
Risk of cardiovascular events following COVID-19 in people with and without pre-existing chronic respiratory disease
Whittaker, H., Kallis, C., Wood, A., Bolton, T., Walker, S., Sheikh, A., Brownrigg, A., Akbari, A., Sterniczuk, K., Quint, J. K.
10.1101/2023.03.01.23286624 — Posted: 2023-03-03
MANAGEMENT OF RISK FACTORS FOR HEALTH CARE WORKERS AFTER INITIAL CONTACT WITH PATIENTS INFECTED WITH SARS-CoV-2 IN NIAMEY, THE CENTER OF THE EPIDEMIC IN NIGER
Ramatoulaye, H. L., Abdal-Kader, A. S., Lagare, A., Maiga, M., Aliane, F. A., Sylviane, F. C. A., Issa, I., Sidikou, B. A., Oumarou, G. I., Aouta, Z. A., Moussa, A., Alassan, Z. D., Karidjo, I., Bachir, G. A. M., Djibo, I., Moussa, S., Maman Laminou, i., Jambou, R.
10.1101/2023.03.01.23286420 — Posted: 2023-03-03
Effectiveness of successive booster vaccine doses against SARS-CoV-2 related mortality in residents of Long-Term Care Facilities in the VIVALDI study
Stirrup, O., Shrotri, M., Adams, N. L., Krutikov, M., Azmi, B., Monakhov, I., Tut, G., Moss, P., Hayward, A., Copas, A., Shallcross, L.
10.1101/2023.03.01.23286627 — Posted: 2023-03-03
SARS-CoV-2 post-vaccine surveillance studies in Australian children and adults with cancer: SerOzNET Quality of Life, Toxicity and Vaccine Beliefs Substudy Statistical Analysis Plan
Donoghue, M. W., Body, A. L., Wakefield, C., Ahern, E. S., Segelov, E.
10.1101/2023.02.28.23286595 — Posted: 2023-03-03
Systematic analyses of the resistance potential of drugs targeting SARS-CoV-2 main protease
Flynn, J. M., Huang, Q. Y. M., Zvornicanin, S. N., Schneider-Nachum, G., Shaqra, A. M., Kurt Yilmaz, N., Moquin, S. A., Dovala, D., Schiffer, C. A., Bolon, D. N. A.
10.1101/2023.03.02.530652 — Posted: 2023-03-02
Assessment of neutralization susceptibility of Omicron subvariants XBB.1.5 and BQ.1.1 against broad-spectrum neutralizing antibodies through epitopes mapping
Woo, H. G., Masaud, S.
10.1101/2023.03.01.530717 — Posted: 2023-03-02
Analysis of SARS-CoV-2 mutations associated with resistance to therapeutic monoclonal antibodies that emerge after treatment.
Focosi, D., McConnell, S., Sullivan, D. J., Casadevall, A.
10.1101/2023.03.02.23286677 — Posted: 2023-03-02
The impact of early anti-SARS-CoV-2 antibody production on the length of hospitalization stay among COVID-19 patients
de Almeida, D. V., Cezar, P. A., Fernandes, T. F. B., Schwarz, M. G. A., Mendonca-Lima, L., Giacoia-Gripp, C. B. W., Cortes, F. H., Lindenmeyer Guimaraes, M., Pilotto, J. H., de Sa, N. B. R., Cazote, A. d. S., Gomes, L. R., Quintana, M. d. S. B., Ribeiro-Alves, M., Coelho, L. E., Geraldo, K. M., Ribeiro, M. P. D., Cardoso, S. W., Grinsztejn, B. G. J., Santos, V. G. V. d., Morgado, M. G.
10.1101/2023.03.02.23286693 — Posted: 2023-03-02

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).